JCO:他汀类药物可能有助改善结肠癌患者生存

2014-08-07 佚名 生物谷

根据一项英国科学家完成的研究证实:他汀类药物(广泛使用的降胆固醇药物),也可提高结直肠癌患者的存活率。早期研究发现:总体而言,相比非使用者,服用他汀类药物如立普妥的结肠癌患者,死于癌症的风险低29%。服用药物超过一年的患者风险甚至减少更多。这些都是观察性研究,还需要进一步研究确认这些初步的研究结果。在确认之后,一项随机试验(病人不知道他们得到是药物还是安慰剂)是必要的,只有在随机对照试验后,才可以

根据一项英国科学家完成的研究证实:他汀类药物(广泛使用的降胆固醇药物),也可提高结直肠癌患者的存活率。

早期研究发现:总体而言,相比非使用者,服用他汀类药物如立普妥的结肠癌患者,死于癌症的风险低29%。服用药物超过一年的患者风险甚至减少更多。

这些都是观察性研究,还需要进一步研究确认这些初步的研究结果。在确认之后,一项随机试验(病人不知道他们得到是药物还是安慰剂)是必要的,只有在随机对照试验后,才可以对患者作出服用他汀类药物的任何建议。

研究人员说,这是迄今为止最大的研究项目,该项目研究了结直肠癌患者使用他汀类药物后生存情况。该研究发表在Journal of Clinical Oncology杂志上,收集了超过7,600名新诊断大肠癌患者相关数据。某些患者,癌细胞已经扩散到邻近的淋巴结。研究人员分析了患者的病史,包括处方记录和死亡记录。

在研究期间,从1998年到2009年,近1,650例患者死于大肠癌。对于使用他汀类药物超过一年的患者,结肠癌死亡的风险下降了36%。而对于那些服用他汀类药物不足一年的患者,风险降低21%。总体来说,他汀类药物的使用与患者死于癌症的几率降低29%是相关的。

然而,研究还未查明他汀类药物的使用与患者死亡几率降低之间是否存在因果关系。通过改善胆固醇水平,他汀类药物可以减缓动脉斑块的形成。究竟这类药物是如何降低结肠癌死亡风险的尚且未知,研究人员说:然而,根据其他研究,他们推测,他汀类药物的功效可能会是阻止正常细胞变成癌细胞,也可能具有杀死癌细胞功效。

American Society of Clinical Oncology的一位女发言人说,结果是“令人鼓舞”的。不过,对于建议服用处方他汀类药物减少结肠癌病人死亡几率,还为时过早。研究人员还指出,他汀类药物治疗癌症的随机试验是必须要首先进行的临床研究.

原始出处

Cardwell CR1, Hicks BM2, Hughes C2, Murray LJ2.Statin Use After Colorectal Cancer Diagnosis and Survival: A Population-Based Cohort Study.J Clin Oncol. 2014 Aug 4.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044357, encodeId=6f9c204435eeb, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Dec 02 19:18:00 CST 2014, time=2014-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891139, encodeId=d744189113914, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Jul 05 17:18:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932506, encodeId=d3361932506ea, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Aug 28 09:18:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10988, encodeId=f3561098848, content=又是一个阿司匹林啊,又有一批文章可以生产了, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5757106889, createdName=oubaochi, createdTime=Fri Aug 08 20:10:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10984, encodeId=4e84109840b, content=如果确实,立普妥又该火一把了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c5c76675, createdName=haoyongbiao, createdTime=Fri Aug 08 11:03:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10968, encodeId=bd4b109685b, content=这个数据还应该进一步累积吧 <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.96.254, createdTime=Thu Aug 07 20:37:00 CST 2014, time=2014-08-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044357, encodeId=6f9c204435eeb, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Dec 02 19:18:00 CST 2014, time=2014-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891139, encodeId=d744189113914, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Jul 05 17:18:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932506, encodeId=d3361932506ea, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Aug 28 09:18:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10988, encodeId=f3561098848, content=又是一个阿司匹林啊,又有一批文章可以生产了, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5757106889, createdName=oubaochi, createdTime=Fri Aug 08 20:10:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10984, encodeId=4e84109840b, content=如果确实,立普妥又该火一把了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c5c76675, createdName=haoyongbiao, createdTime=Fri Aug 08 11:03:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10968, encodeId=bd4b109685b, content=这个数据还应该进一步累积吧 <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.96.254, createdTime=Thu Aug 07 20:37:00 CST 2014, time=2014-08-07, status=1, ipAttribution=)]
    2015-07-05 lidong40
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044357, encodeId=6f9c204435eeb, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Dec 02 19:18:00 CST 2014, time=2014-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891139, encodeId=d744189113914, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Jul 05 17:18:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932506, encodeId=d3361932506ea, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Aug 28 09:18:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10988, encodeId=f3561098848, content=又是一个阿司匹林啊,又有一批文章可以生产了, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5757106889, createdName=oubaochi, createdTime=Fri Aug 08 20:10:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10984, encodeId=4e84109840b, content=如果确实,立普妥又该火一把了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c5c76675, createdName=haoyongbiao, createdTime=Fri Aug 08 11:03:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10968, encodeId=bd4b109685b, content=这个数据还应该进一步累积吧 <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.96.254, createdTime=Thu Aug 07 20:37:00 CST 2014, time=2014-08-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2044357, encodeId=6f9c204435eeb, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Dec 02 19:18:00 CST 2014, time=2014-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891139, encodeId=d744189113914, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Jul 05 17:18:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932506, encodeId=d3361932506ea, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Aug 28 09:18:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10988, encodeId=f3561098848, content=又是一个阿司匹林啊,又有一批文章可以生产了, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5757106889, createdName=oubaochi, createdTime=Fri Aug 08 20:10:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10984, encodeId=4e84109840b, content=如果确实,立普妥又该火一把了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c5c76675, createdName=haoyongbiao, createdTime=Fri Aug 08 11:03:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10968, encodeId=bd4b109685b, content=这个数据还应该进一步累积吧 <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.96.254, createdTime=Thu Aug 07 20:37:00 CST 2014, time=2014-08-07, status=1, ipAttribution=)]
    2014-08-08 oubaochi

    又是一个阿司匹林啊,又有一批文章可以生产了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2044357, encodeId=6f9c204435eeb, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Dec 02 19:18:00 CST 2014, time=2014-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891139, encodeId=d744189113914, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Jul 05 17:18:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932506, encodeId=d3361932506ea, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Aug 28 09:18:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10988, encodeId=f3561098848, content=又是一个阿司匹林啊,又有一批文章可以生产了, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5757106889, createdName=oubaochi, createdTime=Fri Aug 08 20:10:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10984, encodeId=4e84109840b, content=如果确实,立普妥又该火一把了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c5c76675, createdName=haoyongbiao, createdTime=Fri Aug 08 11:03:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10968, encodeId=bd4b109685b, content=这个数据还应该进一步累积吧 <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.96.254, createdTime=Thu Aug 07 20:37:00 CST 2014, time=2014-08-07, status=1, ipAttribution=)]
    2014-08-08 haoyongbiao

    如果确实,立普妥又该火一把了。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2044357, encodeId=6f9c204435eeb, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Dec 02 19:18:00 CST 2014, time=2014-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891139, encodeId=d744189113914, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Jul 05 17:18:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932506, encodeId=d3361932506ea, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Aug 28 09:18:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10988, encodeId=f3561098848, content=又是一个阿司匹林啊,又有一批文章可以生产了, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5757106889, createdName=oubaochi, createdTime=Fri Aug 08 20:10:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10984, encodeId=4e84109840b, content=如果确实,立普妥又该火一把了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c5c76675, createdName=haoyongbiao, createdTime=Fri Aug 08 11:03:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10968, encodeId=bd4b109685b, content=这个数据还应该进一步累积吧 <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.9.96.254, createdTime=Thu Aug 07 20:37:00 CST 2014, time=2014-08-07, status=1, ipAttribution=)]
    2014-08-07 175.9.96.254

    这个数据还应该进一步累积吧

    0

相关资讯

Diabetes:他汀类药物或和糖尿病发生直接相关

近日,刊登在国际杂志Diabetes上的一篇研究论文中,来自麦克马斯特大学的研究人员通过研究发现了一种抑制他汀类药物对机体副作用的新型方法,他汀类药物是一种降低胆固醇及抑制心脏疾病的药物;文章中,研究人员发现了一种连接他汀类药物和糖尿病之间的路径,这项研究或为开发新一代他汀类药物提供了一定思路。 大约1300万人或超过40岁以上的人群都使用过他汀类药物;研究者Schertzer说道,他汀类药物在

EJPC&AIM:两独立研究证实他汀类药物几无额外副作用

尽管临床试验一直在证明他汀类药物的收益,但有些观点认为这类药物会导致严重副作用,促使一些患者中止或不服用这类药物。现在有两项独立研究,一项是大规模的荟萃分析,另一项是只有少量患者参与的研究,提示人们此前大多数被认为与他汀类药物有关的副作用似乎并不是由这类药物引起。 大规模荟萃分析 这项荟萃分析发表在《欧洲心脏病预防杂志》上,有8300名患者被随机配给他汀类药物或安慰剂。英国研究人员

BMJ:已发表论文中撤销他汀不良事件论断

英国医学杂志》(BMJ)宣布,发表于该杂志的一项研究论文删除了他汀类相关性不良事件患者发生百分比的论断,但此项研究尚未被该杂志撤销。 此项研究对心血管疾病低风险患者是否应服用降脂药物提出了疑问。该研究特别指出,在接受他汀类治疗的患者中,约18%~20%出现包括肌肉症状、糖尿病风险、肝脏炎症、白内障、精力减退、性功能障碍和疲乏在内的副作用。上述数据来源于一项观察性研究所报告的他汀类

争议:他汀类药物是否增加急性肾损伤风险?

Heartwire报道称,温哥华哥伦比亚大学Dormuth教授等对使用瑞舒伐他汀≥10mg/天、阿托伐他汀≥20mg/天、辛伐他汀≥40mg/天的三组患者进行观察研究,研究数据来自于加拿大、美国及英国200多万患者。结果发现与使用低剂量的他汀类药物相比,这些患者在接受高剂量他汀类药物治疗的最初4个月,发生急性肾损伤的风险增高34%。 因此,Dormuth教授认为,高剂量他汀类药物会增加患者急

胡大一:我国当前血脂异常治疗的15条建议

血脂异常的治疗成为2013年下半年心血管医学界最引入关注的热门话题。继先前发布的欧洲心脏病学学会和欧洲动脉粥样硬化学会指南之后,2013年7月和12月分别公布了国际动脉粥样硬化学会(IAS)的建议和美国心脏协会(AHA)/美国心脏病学学会(ACC)的指南。这3个学术影响较大的指南类文件在形式与内涵上出现了巨大差别,引起了国内外学术机构与广大临床医生的关注与质疑。国内已开展了多次讨论,2007年

Drug Saf:他汀类药物治疗可导致睡眠障碍

当前,他汀类药物治疗对睡眠质量的可能影响受到越来越多的关注。然而,目前尚无某种特定他汀类药物比其他药物更有可能导致睡眠障碍的结论性证据。而且,不同种类他汀类药物是否会产生不同的睡眠障碍风险也不清楚。 为此,来自日本近畿大学药学院的Mitsutaka Takada教授及其团队进行了一项研究,调查他汀类药物治疗和睡眠障碍风险之间的关系。该研究结果发表在2014年06月的Drug Safety杂志上。